|Articles|March 15, 2022

BioPharm International

  • BioPharm International, Regulatory Sourcebook March 2022
  • Volume 2022 eBook
  • Issue 1
  • Pages: 24-29

A New Route to Pharma GDP Compliance and Standardization

A consensus-based approach to GDP lies at the heart of a new industry-wide program seeking to rationalize, standardize, and harmonize the adherence to pharma transportation norms and regulatory guidelines.

The logistics associated with the safe and efficient physical transportation of pharmaceuticals is increasingly taxing the minds of logisticians as medicines become more complex and labile and their regulatory oversight intensifies. The statutory need to maintain the therapeutic and physical integrity of drugs during transit renders the management of quality and the adherence to good distribution practice (GDP) guidelines an absolutely critical part of the pharmaceutical supply process.

Read this article in Pharmaceutical Technology’s March 2022 Quality and Regulatory Sourcebook eBook.

About the author

Courtney Soulsby is sector director, Healthcare & Life Sciences, BSI.

Alan Kennedy is director, Team Poseidon.

Article Details

BioPharm International eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 24–29

Citation

When referring to this article, please cite it as C. Soulsby, A. Kennedy, “A New Route to Pharma GDP Compliance and Standardization," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).

Articles in this issue

almost 4 years ago

In-Use Testing of Cleanroom Garments

almost 4 years ago

How a Lack of Critical Thinking is Hindering Regulatory Compliance

almost 4 years ago

Contextualizing Computer Validation

almost 4 years ago

Assessing the Quality of CAR-T Cells Using ddPCR

almost 4 years ago

The Data Relationship

almost 4 years ago

Supply Chain Considerations for Ensuring Quality

almost 4 years ago

DSCSA’s Next Big Hurdle

almost 4 years ago

Remote Inspections - Lessons Learned

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content